How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

As drug discovery moves from trial-and-error to digital simulation, choosing between Recursion Pharmaceuticals (NASDAQ:RXRX) and Schrödinger (NASDAQ:SDGR) depends on ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

The companies at the frontier of artificial intelligence should be ready to slow down, one of the fastest-moving among them says. Anthropic, the maker of the Claude chatbot, has claimed AI systems may ...

Christopher Gibson, Co-Founder and CEO, announced, "beginning January 1, the amazing Najat Khan is going to take over the role of CEO, President and Director of Recursion." Gibson will transition to ...

Recursion Pharmaceuticals uses its AI-driven platform to manage a deep pipeline of drug candidates through strategic partnerships with industry giants. Schrödinger leverages physics-based software to ...

Join the Tom's Guide Club for quick access. Enter your email below and we'll send confirmation, and sign you up to our newsletter.

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Arthur Gies Arthur Gies is an editor for Wirecutter's tech coverage. He's ...